STEPHEN HIX: Open Payments
NPI 1477224392 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,622 in 71 payments from 23 companies in 2025. Trend: 2023 $1,008 · 2024 $1,313 · 2025 $1,622
Food & beverage: $1,622
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $234 |
| Madrigal Pharmaceuticals | 6 | $204 |
| SHIELD THERAPEUTICS INC | 3 | $159 |
| AstraZeneca Pharmaceuticals LP | 8 | $148 |
| Merck Sharp & Dohme LLC | 4 | $92 |
| Aimmune Therapeutics, Inc. | 5 | $87 |
| Janssen Biotech, Inc. | 5 | $85 |
| GENZYME CORPORATION | 4 | $83 |
| Novartis Pharmaceuticals Corporation | 3 | $71 |
| Daiichi Sankyo Inc. | 3 | $69 |
Products named: REZDIFFRA, ACCRUFER, ENTYVIO, LYNPARZA, KEYTRUDA, TREMFYA, DUPIXENT, EOHILIA.
Industry payments across OK — which companies pay providers there.
